📋 Tender Overview
PPD Inc. a leading global contract research organization is opening a new laboratory in Suzhou China to support China-based biotech companies and Western pharmaceutical companies managing China research studies. The 67000-square-foot 6224-square-meter facility in the Suzhou New District Jiangsu Province is expected to be fully operational in 2021 offering bioanalytical biomarker and vaccine services to support trials across all phases of pharmaceutical development. The company anticipates adding approximately 350 positions as a result of the expansion.Integrating three sophisticated laboratories in one strategic location will make our new China facility a premier destination for biopharma customers seeking high-caliber lab services to accelerate clinical research within China and on the global stage said Christopher Fikry M.D. executive vice president of PPD Laboratories. Adding Suzhou to our central labs in Shanghai and Singapore expands the scope of our global laboratory footprint to help our customers advance drug development for patients across the world particularly at a time when so much of our focus is on supporting trials aimed at developing vaccines and treatments for COVID-19.In Suzhou the bioanalytical lab offering will include services for small molecules biologics and cell and gene therapies. The lab will encompass multiple technology platforms across a wide range of applications including ligand-binding immunochemistry liquid chromatography tandem mass spectrometry LC-MSMS polymerase chain reaction PCR and flow cytometry. The lab will specialize in the development and validation of fully compliant robust custom assays for pharmacokineticpharmacodynamic PKPD analyses and immunogenicity assessments in both preclinical and clinical studies.The biomarker lab offering will include a range of services applicable across multiple regulatory compliance environments and fit-for-purpose situations. Analysis will be performed with molecular genomics flow cytometry ligand binding and LC-MSMS to support both preclinical and clinical studies. PPDs alliance with NeoGenomics Laboratories enhances its internal capabilities with extensive immunohistochemistry and molecular test menus. NeoGenomics operates an oncology-focused clinical trials testing lab in the same building as the PPD Laboratories central lab in Singapore and plans to establish a similar arrangement in PPDs new Suzhou facility.The vaccine sciences lab will provide a full range of testing services specifically designed for vaccine development trials. The lab will employ immunoassays cell-based assays and multiplexed functional assays for vaccine efficacy and molecular assays for infectious disease monitoring. The labs services will span technology assessment and method development to immunogenicity and concomitant studies.In the Asia-Pacific region PPD also maintains a central lab in Shanghai that provides support for clinical trials being conducted in China with safety and efficacy testing custom specimen collection kits and biorepository services. The lab provides high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development. The central labs innovative enterprise and information management system the Preclarus central lab database delivers data in real time to expedite project teams decision-making and help accelerate research.In addition to the new lab in Suzhou PPD Laboratories includes bioanalytical labs in Middleton Wisconsin and Richmond Virginia GMP good manufacturing practices labs in Athlone Ireland and Middleton central labs in Shanghai China Brussels Belgium Highland Heights Kentucky and Singapore biomarker labs in Highland Heights and Richmond and a vaccine sciences lab in Richmond.